Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study)

Completed

Conditions studied: Lymphoma, Follicular

In brief

The F2-study is a complement of the previous studies of the Follicular Lymphoma Prognostic Factors Project which permitted the development of the Follicular Lymphoma International Prognostic Index (FLIPI). The F2-study is designed as a prospective collection of information potentially useful to predict the prognosis of newly diagnosed Follicular Lymphoma patients, and its purposes are to validate the FLIPI and to verify whether a prognostic collection of data would allow the development of a more accurate prognostic index.

Key facts

Study ID

NCT01250223

Run by

Associazione Angela Serra per la ricerca sul cancro

People needed

1093

Starts

2003-02-01

Expected to finish

2016-12-01

Last updated by the study team

2020-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with newly diagnosed follicular lymphoma
• Patients with histologically confirmed diagnosis of follicular lymphoma according to WHO classification (any grade)
• Age over 18
• Written informed consent

You may not qualify if…

• None

Where it is running

• University of Nebraska Medical Center — Omaha, Nebraska, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• Academia Nacional de Medicina - Oncohematology Department, Instituto de Investigaciones Hematologicas — Buenos Aires, Argentina
• Centro de Internacion e Investigacion Clinica "Angelica Ocampo" - Hematologia — Buenos Aires, Argentina
• Charles University General Hospital - Ist Dept Medicine — Prague, Czechia
• Centre Hospitalier Universitaire - Hématologie — Besançon, France
• Institut Bergonié Comprehensive Cancer Center — Bordeaux, France
• Centre Jean Bernard, Clinique Victor Hugo — Le Mans, France
• Centre Hospitalier Univeristaire - Hématologie clinique — Nantes, France
• Hopital caremeau - Service de Medecine Interne B — Nîmes, France
• CHRU Bretonneau - Oncologie medicale — Tours, France
• Presidio Spedali Civili — Brescia, BS, Italy
• Azienda Ospedaliera S. Croce e Carle — Cuneo, CN, Italy
• Azienda O.U. Vittorio Emanuele-Ferrarotto-S. Bambino — Catania, CT, Italy
• Azienda Ospedaliera Pugliese-Ciaccio — Catanzaro, CZ, Italy
• Ospedale Casa Sollievo della Sofferenza IRCCS — San Giovanni Rotondo, FG, Italy
• Ospedale unico Versilia USL 12 - Divisione di Medicina II, DH Oncoematologico — Lido di Camaiore, Lucca, Italy
• Ospedale San Vincenzo - Ematologia e Immunologia — Taormina, Messina, Italy
• Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte — Messina, ME, Italy
• Istituto Clinico Humanitas — Milan, MI, Italy
• Istituto Scientifico Universitario San Raffaele — Milan, MI, Italy
• Istituto Europeo di Oncologia — Milan, MI, Italy
• Ospedale Madonna delle Grazie — Matera, Mount, Italy
• Dipartimento di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio, Univ. di Modena e Reggio Emilia - Ematologia — Modena, MO, Italy
• Northwestern University Feinberg School of Medicine - Department of Hematology/Oncology — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.